Shareholder Returns
Information on Sumitomo Pharma’s shareholder returns.
Dividend
For the FY2022 interim dividend, the Company has decided to pay an ordinary dividend of 14 yen per share. As a result of posting an impairment loss on multiple products due to slow sales and unsuccessful development in FY2022, the Company had posted a significant loss in operating income and net profit attributable to owners of parent. Accordingly, the Company has decided to pay a year- end dividend for FY2022 of 7 yen per share, for a total annual dividend of 21 yen for FY2022 (consolidated dividend payout ratio ― ). During the Mid-term Business Plan 2027 period, the Company will suspend dividends as negative core operating profit is forecasted for the year ending March 31, 2024 but will resume dividends for the year ending March 31, 2025 as core operating profit is expected to return to positive. A consistent dividend payout will be the aim thereafter.
The Company would like to extend its deepest apologies to its shareholders. The Company will make every effort to promptly recover its performance, and the Company would appreciate your understanding and continued support.
We have not split or consolidated our shares during the periods shown in the table below.
FY2021 | FY2022 | FY2023 (tentative) | |
---|---|---|---|
Consolidated dividend payout ratio | 19.7% | ー | ー |
Our basic policy on profit distribution
The Company believes it important to distribute surpluses in an appropriate manner reflecting any improvement in its performance. Accordingly, a performance-linked dividend hike will be considered in addition to consistent dividend payout.
Pursuant to this fundamental policy, during the Mid-term Business Plan 2027 period, the Company will suspend dividends as negative core operating profit is forecasted for the year ending March 31, 2024 but will resume dividends for the year ending March 31, 2025 as core operating profit is expected to return to positive. A consistent dividend payout will be the aim thereafter.
Dividend per share
Share repurchase
No share repurchase is currently taking place.
Shareholder incentives
No shareholder incentive program is currently taking place.